OCC didn't mention a NDA was in place.Usually a company shouts...

OCC didn't mention a NDA was in place.

Usually a company shouts the good results from the rooftop. They have tried a bit.

We have sales price and quantities. A margin should be able to be calculated by well informed fund analysts. Even a conservative margin.

Striate sells for 136USD and productions plans for 100,000 are in place. 5M income is pretty safe bet I reckon. PE of 30 and we are MC of 150M. Twice where we are now.

A week of presentations were made a couple of weeks ago. Don't think it got traction.

I think there is somebody else keeping the SP down.

Maybe somebody working for a large pharma with eyes on the products being developed by OCC.

We might never realize the potential of this company and end up with a low ball takeover offer.

But a manipulator cant stop serious interest from multiple funds. I question whether the funds are convinced that OCC products are unique. Collagen has been around a while. The fund analysts need to know REMPLIR and ATI are unique. Game changing products.

The SP is a cent above where it was BEFORE the biohorizon annc. 38.5c Seriously dismal. Might level with or go below soon.

How the market responds to the remplir announcement coming soon will be very telling.